Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics appoints ex- Skyepharma man as FD

Peter Jensen, Allergy’s chairman said Wykeham’s experience in life sciences was well suited to Allergy.
Picture of handshake
New Allergy FD is experienced life sciences specialist

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has appointed Nick Wykeham as its new finance director.

Wykeham, 51, was group financial controller at Skypharma until August last year, with a stint at ICI business Quest prior to that.

Peter Jensen, Allergy’s chairman said Wykeham’s experience in life sciences was well suited to Allergy.  

He replaces Ian Postlethwaite who resigned in March after 14 years with the company and taken up the post of chief financial officer at healthcare company investor NetScientific (LON:NSCI).

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Related Articles

eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
picture of drug research
February 20 2017
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use